International Guideline Harmonization Group
  • Home
  • About IGHG
    • Members
      • Core group
      • Guideline panels
        • Breast cancer
        • Cardiomyopathy
        • Premature ovarian insufficiency
        • Male gonadotoxicity
        • Thyroid cancer
        • Ototoxicty
        • Obstetric care
        • Central nervous system neoplasms
        • Fatigue, mental health and psychosocial problems
        • Fertility preservation
        • Hypothalamic-pituitary dysfunction
        • Coronary artery disease
        • Metabolic syndrome
        • Pulmonary dysfunction
        • Bone mineral density
        • Hepatic toxicity
        • Nephrotoxicity
        • Neurocognitive problems
        • Colorectal cancer
        • Thyroid dysfunction
        • Splenic dysfunction
        • Dexrazoxane cardioprotection
        • Growth hormone treatment
        • COVID-19 Statement
    • Collaborators
    • Funding sources
    • Methods
      • Process
      • Grading system
      • Topic selection
      • Publication
      • Handbook
  • Guidelines
    • Topics
      • Breast cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Cardiomyopathy
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Premature ovarian insufficiency
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Male gonadotoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Thyroid cancer
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Ototoxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Obstetric care
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Central nervous system neoplasms
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fatigue
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Psychosocial problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Mental health problems
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Coronary artery disease
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Fertility preservation
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publications
        • Guideline panel
      • Bone mineral density
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hepatic toxicity
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Hypothalamic-pituitary dysfunction
        • Guideline panel
      • Metabolic syndrome
        • Guideline panel
      • Nephrotoxicity
        • Guideline panel
      • Colorectal cancer
        • Guideline panel
      • Neurocognitive problems
        • Guideline panel
      • Pulmonary dysfunction
        • Guideline panel
      • Splenic dysfunction
        • Guideline panel
      • Dexrazoxane cardioprotection
        • Recommendations
        • Conclusions of evidence
        • Evidence tables
        • Publication
        • Guideline panel
      • Growth hormone treatment
      • Thyroid dysfunction
        • Guideline panel
      • COVID-19 Statement
  • Patient education
  • News
  • Meetings
  • Contact

News

Home News

News archive

  • May 2022
  • March 2021
  • October 2020
  • September 2020
  • April 2020
  • February 2019
  • January 2017
  • August 2016
  • July 2016
  • April 2015
  • September 2014
  • October 2013
  • May 18, 2022

    International Symposium on Late Complications after Childhood Cancer – ISLCCC 2022

    We are pleased to announce the first ISLCCC meeting will be convened on 8-9 July 2022 at the Princess Máxima Center for pediatric oncology in Utrecht, the Netherlands. The meeting will include Read more

  • March 15, 2021

    Kick off expert panel splenic dysfunction

    We will soon initiate the harmonization of the splenic dysfunction surveillance guideline. Please contact us if you are interested in participating in this guideline panel.

    Read more
  • October 21, 2020

    New guidelines published

    The following guidelines have been published or accepted for publication:

    • Updated breast cancer surveillance recommendations in the Journal of Clinical Oncology
    • Obstetric care recommendations in the American Journal Read more
  • September 01, 2020

    The impact of COVID-19 on survivorship care: an IGHG questionnaire study

    The IGHG COVID-19 working group is currently researching how the outbreak of COVID-19 has impacted the delivery of survivorship care for survivors of childhood, adolescent and young adult cancer. In this Read more

  • April 07, 2020

    IGHG COVID-19 Statement

    Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus.

    The IGHG COVID-19 working group developed a statement to provide guidance to childhood, adolescent and young adult Read more

123456
  • Contact
  • Disclaimer

© International Guideline Harmonization Group